Gland Pharma announced that following the Inspection for Good Manufacturing Practices (GMP) by US FDA at the Company`s Pashamylaram Facility at Hyderabad between 25 July, 2024 and 02 August, 2024; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.Powered by Capital Market - Live News

Gland Pharma will hold a meeting of the Board of Directors of the Company on 3 February 2025.Powered by Capital Market - Live News

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vitamin K1 Injectable Emulsion USP, 10 mg/mL, of Hospira, Inc.This Product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.The Company expects to launch this Product through its marketing partners in the near future. According to IQVIA, the product had US sales of approximately USD 15 million for the twelve months ending September 2024. Powered by Capital Market - Live News

Net profit of Gland Pharma declined 15.74% to Rs 163.53 crore in the quarter ended September 2024 as against Rs 194.08 crore during the previous quarter ended September 2023. Sales rose 2.36% to Rs 1405.83 crore in the quarter ended September 2024 as against Rs 1373.42 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1405.831373.42 2 OPM %21.1323.60 - PBDT350.60371.19 -6 PBT256.78289.89 -11 NP163.53194.08 -16 Powered by Capital Market - Live News

Gland Pharma will hold a meeting of the Board of Directors of the Company on 4 November 2024.Powered by Capital Market - Live News